Abstract
Targeted therapies against Programmed Death Ligand 1 (PD-L1) in advanced NSCLC has revolutionized the management in recent years. As there is limited data on the significance of PD-L1 expression in NSCLC from India, we aimed to study the prevalence of PD-L1 expression and its relation with different clinic-pathological parameters in patients of stage IV NSCLC from a tertiary care centre in Eastern India
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
